InvestorsHub Logo
Followers 88
Posts 1168
Boards Moderated 0
Alias Born 09/10/2017

Re: longfellow95 post# 238826

Thursday, 08/08/2019 12:49:28 AM

Thursday, August 08, 2019 12:49:28 AM

Post# of 701646

What do NWBO expect to gain? Unless it's to demonstrate that the DCVax-L arm is more effective and safer than the DCVax-L plus Nivo arm.


I think Northwest Bio (along with the UCLA Neuro-Oncology Dept.) hope that the combination will have a synergistic effect and will help a broader range of patients than with DCVax-L alone. And I’m sure that Bristol Myers is not only hoping the same, but also that the combination will be safer than NIVO alone.

Remember this article by Liau, Cloughesy, Prins et. al?

PD-1 blockade enhances the vaccination-induced immune response in glioma
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4951098/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News